OTDOncology Treatment Discovery3083-49962981-8079Bio-Byword Scientific Publishing Pty. Ltd.10.26689/otd.v3i2.11071ArticleResearch Progress on Malignant Peritoneal Effusion in Gastrointestinal Tumorshttps://artdesignp.com/journal/OTD/3/2/10.26689/otd.v3i2.11071CaoHongli,ZhangGangling,CuiYizheng,TaoRancen,LiJie2025322025-07-08Malignant Peritoneal Effusion (MPE) in gastrointestinal tumors can affect the prognosis of patients with advanced cancer. It is associated with multiple factors such as abnormal angiogenesis, a damaged lymphatic system, and an inflammatory response. After the onset of the disease, tumor cells invade the peritoneum, and changes in the peritoneal microenvironment can increase vascular permeability. Additionally, factors such as the high number of neovascularizations in patients with malignant tumors, lymphatic circulation disorders, and intensified inflammatory responses in the body create a vicious cycle, leading to increased production of ascites. Clinically, imaging techniques, cytological techniques, and biomarker detection techniques are commonly used to diagnose MPE, and treatment options and prognostic factors are explored through clinical practice. This study analyzes the diagnosis and treatment methods of MPE from multiple perspectives, providing a basis for summarizing new diagnosis and treatment methods for MPE in the later stage.

Cao C, 2016, Expression of miRNA-21 in Imatinib-Sensitive Gastrointestinal Stromal Tumors and Its Mechanism of Action Through B-lymphoma-2 Gene Locus, thesis, Southern Medical University.

Wang Y, 2021, Analysis of the Optimal Population for the Treatment of Colon Cancer Ascites With Huachansu Injection and Its Mechanism of Action on VM, thesis, Beijing University of Chinese Medicine.

Jin F, 2022, Research Progress on the Mechanism and Treatment of Peritoneal Metastasis in Epithelial Ovarian Cancer. Chongqing Medicine, 51(12): 2140–2144.

Seimetz D, 2011, Novel Monoclonal Antibodies for Cancer Treatment: The Trifunctional Antibody Catumaxomab (Removab). J Cancer, 2: 309–316.

Kim H, Yang Y, Byeon S, et al., 2021, E-Cadherin and Angiopoietin-2 as Potential Biomarkers for Colorectal Cancer With Peritoneal Carcinomatosis. Anticancer Res, 41(9): 4497–4504.

Lasry A, Zinger A, Ben-Neriah Y, 2016, Inflammatory Networks Underlying Colorectal Cancer. Nat Immunol, 17(3): 230–240.

Chinese Research Hospital Association Minimally Invasive Surgery Professional Committee, Laparoscopic Surgery Magazine Editorial Department, 2019, Expert Consensus on the Application of Circulating Tumor Cell Detection in Colorectal Cancer (2018). Journal of Laparoscopic Surgery, 24(1): 74–80.

Yuan J, Luo W, Mo H, et al., 2024, Clinical Analysis of 189 Cases of Gastrointestinal Malignant Tumors Treated With Intraperitoneal Hyperthermic Chemotherapy. Chinese Journal of Modern Operative Surgery, 28(2): 85–90.

Bang Y, Cutsem E, Feyereislova A, et al., 2010, Trastuzumab in Combination With Chemotherapy Versus Chemotherapy Alone for Treatment of HER2-Positive Advanced Gastric or Gastro-Oesophageal Junction Cancer (ToGA): A Phase 3, Open-Label, Randomised Controlled Trial. Lancet, 376(9742): 687–697.

Cui J, 2019, Surgical Treatment and Prognostic Factors Analysis of Hepatolithiasis-Related Intrahepatic Cholangiocarcinoma, thesis, Chinese People’s Liberation Army Military Medical University.